Health Net Begins Coverage of Biodesix's VeriStrat | GenomeWeb

NEW YORK (GenomeWeb) – Biodesix today announced that Health Net has issued a positive coverage decision for the VeriStrat test. 

According to Biodesix, Health Net considers the test medically necessary for patients with advanced non-small cell lung cancer and wild-type EGFR or with unknown EGFR status. Health Net covers about 5.9 million lives, primarily on the US West Coast. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.